With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.83570-42-7,1-(Quinoxalin-6-yl)ethanone,as a common compound, the synthetic route is as follows.
Titanium tetraisopropoxide (0.08 mL, 0.27 mmol) was added to a stirred suspension of Intermediate 3b (57 mg, 0.25 mmol) and l-(quinoxalin-6-yl)ethanone (CAS: 83570-42- 7; 50 mg, 0.29 mmol) in THF (1.5 mL) at rt and under N2 atmosphere. The mixture was stirred into a sealed tube at 80 C for 16 h. Then sodium cyanoborohydride (28 mg, 0.45 mmol) was added and the mixture was further stirred at 80 C for 16 h. Then, NaHC03 (aq. sat. soltn.) and DCM were added to the mixture. The solvent was evaporated in vacuo and the crude product was purified by flash column (0323) chromatography (silica gel, 7N solution of NH3 in MeOH in DCM, from 0/100 to 10/90) and then by RP HPLC (Stationary phase: C18 XBridge 30 x 100 mm 5 muetaiota; mobile phase: gradient from 81 % 1 OmM NH4CO3H pH 9 solution in water, 19% (0324) CH3CN to 64% lOmM NH4CO3H pH 9 solution in water, 36% CH3CN). The desired fractions were collected and concentrated in vacuo to yield product 7 (10 mg, 10%> yield) as yellow oil., 83570-42-7
As the paragraph descriping shows that 83570-42-7 is playing an increasingly important role.
Reference£º
Patent; JANSSEN PHARMACEUTICA NV; BARTOLOME-NEBREDA, Jose Manuel; TRABANCO-SUAREZ, Andres Avelino; MARTINEZ VITURRO, Carlos Manuel; (116 pag.)WO2018/141984; (2018); A1;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider